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Referat: 
Cancer is one of the main causes of death in developed countries, and cancer 
treatment heavily depends on successful early detection and diagnosis. Tumor 
biomarkers are helpful for early diagnose. The goal of this discovery method is to 
identify genetic variations as well as changes in gene expression or activity that 
can be linked to a typical cancer state. 
First, several cancer gene signaling pathways were introduced and then com-
bined. 27 candidate genes were selected, through the analysis of several data 
sets in the GEO database, a few expression difference matrices were established. 
Those candidate genes were tested in the matrices and found five genes PLA1A, 
MMP14, CCND1, BIRC5 and MYC that have the potential to be tumor biomarkers. 
Two of these genes have been further discussed, PLA1A is a potential biomarker 
for prostate cancer, and MMP14 can be considered as a biomarker for NSC lung 
cancer. 
Finally, the significance of this study and the potential value of the two genes are 
discussed, and the future research in this direction is a prospect. 
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1 Motivation 
Cancer is generally known as a group of diseases that can affect any part of the 
body. Other terms of cancer are malignant tumor and neoplasm. One defining fea-
ture of cancer is the rapid growth of abnormal cells that go beyond their usual bor-
ders to grow, invade adjacent parts of the body, and spread to other organs that are 
known as metastases. Metastasis is the leading cause of death from cancer. In 2012, 
there are about 14 million new cases of cancer and 8 million 200 thousand cases of 
cancer-related death [Ferlay J et al.,2013]. It is supposed that the number of new 
cancer cases will increase by 70% in the next twenty years. In 2012, the five most 
commonly diagnosed cancers of the men were lung cancer, prostate cancer, colo-
rectal cancer, stomach cancer and liver cancer. The five most diagnosed common 
cancer of the women were mammary, colorectal cancer, lung cancer, cervical can-
cer, and gastric cancer [Bernad w et al.,2014].  
If the patients were fund cancer and received treatment as soon as possible, they 
can reduce the mortality rate of cancer. There are two components in the early de-
tection. One is the early diagnosis. Pay attention to early signs and symptoms (such 
as skin cancer, cervical cancer, breast cancer, colorectal cancer, and oral cancer), 
so that the disease can be diagnosed and treated in the earlier stage. Early diagno-
sis planning is particularly useful in the absence of effective screening methods (e.g., 
in the environment of the absence of a lot of resources) or therapeutic measure. 
Under the circumstance of the absence of any early detection or screening and 
treatment measures, the patient will be diagnosed at a late stage, at that time patient 
is often untreatable. The other is screening. The purpose of screening is to identify 
individuals who have an abnormal phenomenon before infecting cancer or the sug-
gestion of some specific cancer, allow them to be treated in a timely manner, or be 
diagnosed and treated in a feasible manner. For common types of cancer, it can be 
used the screening test method that is cost-effective, affordable, and can be ac-
cepted and obtained for most high-risk groups. In this case, the screening program 
is especially effective. Screening methods include: using acetic acid for visual in-
spection of the cervical cancer in the environment of the lack of resources; conduct 
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human papillomavirus examination for cervical cancer; make PAP smear examina-
tion for cervical cancer for the use of medium and high income people; conduct 
breast screening for breast cancer in the environment of high income. Treatment of 
cancer: accurate diagnosis of cancer is essential to take appropriate and effective 
treatment measures, because each type of cancer require specific treatment options, 
including the use of one or more methods, such as surgery, and/or radiotherapy, 
and/or chemotherapy. The primary goal of the treatment is to cure cancer or prolong 
life. Improving the quality of life for patients is also an important goal.  
The effectiveness of treatment and cure of medical science for cancer depends on 
whether cancer can be detected timely in the early stages. 
As one of the most direct and rapid diagnostic methods, the screening and obtaining 
of biomarkers play a critical role in many aspects of diagnosis, development, treat-
ment, and therapeutic effect monitoring of tumor. 
Cancer biomarkers are wildly used in clinic trials, and many types of research of 
finding the novel biomarkers have been taking for many years. But how the search-
ing processes would undertake by using the open-resource?  
In this work, two databases, KEGG and GEO, were used to find the potential cancer 
biomarker candidates. And the processes of this work can roughly be partitioned 
into two aspects. First, using the pathway map of KEGG, to find the suitable candi-
date genes, according to the understanding of different pathways. On the other hand, 
many data sets were collected from GEO database and using the statistical analysis 
to find the candidate genes, which overexpressed in a cancer sample. 
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2 Introduction 
2.1 The worldwide situation of cancer                                                                                      
Over 60% of the world's new cancer cases occur in Africa, Asia, Central America 
and South America, which accounts for about 70% of the world's total cancer deaths. 
In the next 20 years, it estimated that annual cancer cases will rise from 14 million 
in 2012 to 22 million. 
There are many problems due to cancer. Cancer is one of the leading causes of 
death in the world, resulting in 8 million 200 thousand deaths in 2012. The main 
types of cancer are: lung cancer (deaths of 1 million 590 thousand cases), hepato-
cellular carcinoma (deaths of 745 thousand cases), gastric cancer (deaths of 723 
thousand cases), colorectal cancer (deaths of 694 thousand cases), breast cancer 
(deaths of 521 thousand cases), esophageal cancer (deaths of 400 thousand cases). 
What is the cause of cancer? Cancer arises from a single cell. There is a multi-stage 
process to go through from a normal cell into a tumor cell, it usually changed into 
malignant tumor from precancerous lesions. These changes are the result of an 
interaction between a person's genetic factors and three external factors that include: 
physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcino-
gens, such as asbestos, tobacco smoke constituents, aflatoxin (a food contaminant) 
and arsenic (a drinking contaminant); and biological carcinogens, such as infections 
caused by certain viruses, bacteria, or parasites [Bernad w et al.,2014].  
WHO carry out the classification of causing factors of cancer, through its interna-
tional cancer research agency (IARC). Aging is another fundamental factor in the 
formation of cancer. Cancer incidence remarkably increases with the growth of age, 
and it is likely due to the accumulation of specific cancer risk factors in someone's 
life history. In addition, as a man grows older, the cell repair mechanism has a ten-
dency to go downhill. There are a lot of risk factors for cancer, for instance, smoking, 
using alcohol, unhealthy diet and lack of physical activity are the main risk factors 
for cancer in the world. Some chronic infections are also a risk factor for cancer, 
these factors have a major impact on the people who are in low and middle-income 
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countries. Hepatitis B virus, hepatitis C virus and some types of HPV individually 
increase the risk of developing liver cancer and cervical cancer. The infection of HIV 
greatly increases the risk of cancer, such as cervical cancer [Engels EA et al., 2008; 
McGinnis KA et al., 2006]. Approximately 1/3 of cancer deaths are derived from five 
major behavioral and dietary risk factors: high body mass index, low intake of fruits 
and vegetables, lack of exercise, using tobacco and alcohol. The use of tobacco is 
the most significant risk factor for cancer, which causes about 20% deaths of the 
world from cancer, and about 70% deaths of the world from lung cancer. For exam-
ple, the death rate due to the infection of hepatitis B virus, hepatitis C virus, and 
human papilloma virus are 20% in the low-income and middle-income countries [De 
Martel C et al.,2012].  
 
2.2 Biomarkers and Tumor biomarkers 
Biomarkers is a kind of indicator that can objectively measure and evaluate normal 
biological processes, pathological process or drug intervention reaction, which is 
also important warning indicators when organism damage, involving changes in the 
molecular structure and function of cells, changes in biochemical metabolism, ab-
normalities of the physiological activity, and abnormal change of individual, group, 
or the entire ecosystem [Atkinson AJ et al.,2001].  
As for biomarker, it can establish drug development, the treatment method, and 
bring new opportunities, in order to provide more safe and effective products and 
services for patients at the same time, which is a strong impetus to the progress of 
medical and biological fields other basic research. Now biomarkers have made 
many breakthroughs, products are also applied to the actual clinical treatment, and 
the development of biomarkers has also promoted the transformation of the re-
search model. In the field of diagnosis, a simple study of one or two biomarkers has 
been transformed into a combination of a variety of markers, and IVDMIA (In Vitro 
Diagnostic Multivariate Index Assays) has been rapid development [HHS et al., 
2012]. In the personalized medicine, the development of biomarkers has played a 
powerful role in promoting the development of personalized medicine. In addition, 
biomarkers can also be used to guide the use of drugs to reduce the cost of adverse 
reactions caused by. However, in the field of medicine, biomarker is an emerging 
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discipline, there are still many problems needing to be solved, mainly in the following 
aspects: how to apply genomics and related research data to clinical research; how 
to enhance cooperation among different databases; how to improve the current reg-
ulation and compensation system of biological markers. To address these issues, 
how to persuade more medical workers to use biological markers related products 
and inspection measuring means will become the key problem, all of these chal-
lenges require the government, research institutions, enterprises and medical work-
ers to work together and corporate with each other. 
The research on biomarkers is not only the important content of the biochemical 
basis, but also has important value in the development of new drugs, medical diag-
nosis, clinical research, and contribute to help researchers to propose more effective 
means of diagnosis and treatment, especially has important value in the prevention 
and control of chronic diseases and complicated diseases, such as tumor, cardio-
vascular diseases, sugar diabetes, neurological disorders [Rundle A et al., 2012]. 
At the end of the 20th century, the development of the omics technology greatly 
promoted the progress and development of the research on biomarkers[Ratain MJ 
et al., 2007], countries (regions) have introduced corresponding support policy, for 
instance, the  U. S. Food and Drug Administration (FDA) introducing the Critical 
Path Initiative (CPI) in 2004[Critical Path, 2011], the European Medicines Agency 
Road Map to 2015, the application and development policy of biological mark of 
OECD in the health field[The European Medicines Agency Road Map to 2015, 2010], 
are all clear on the key role of biomarkers in the development of new drugs and 
clinical treatment. Overall, the roles of biological markers in countries (regions) are 
summarized in the following three aspects: the new biomarkers have become the 
basis of preventive medicine, put forward measures to reduce the prevalence and 
risk before the occurrence of the disease[Nalejska et al.,2014]; using biomarkers in 
evidence-based medicine improve the quality of diagnosis or treatment and reduce 
the impact of disease on society and the economy [Holliday EG et al.,2010]; bi-
omarker changes the existing medical model, and promote the development of per-
sonalized medicine, and take a more active and effective treatment for specific pa-
tients[Personalized Medicine Coalition,2014]. 
Comprehensively and systematically sort out and analyze the current status and 
trends of domestic and international biomarkers, so as to provide Bibliography for 
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the basic research of Biochemistry and new drug development, medical diagnosis, 
clinical research. Since the beginning of this century, the development of basic re-
search on biomarkers is rapid, many countries have introduced corresponding re-
search program and policy support, promoting knowledge sharing and creation and 
ensuring the sustainable development in the field of medicine. Under the impetus of 
the parties, the basic research results of biological markers have been rapid growth. 
In the development of research and application of biomarkers, the construction of 
infrastructure is necessary [Policy Issues for the Development and Use of Bi-
omarkers in Health,2010]. Because biomarker research is the most basic work for 
specific disease states or biological process, but screening of suitable biomarkers 
will often encounter the following two questions: on the one hand, the genome pro-
ject provides a large number of potential biomarkers, but it is very difficult to find 
clinically relevant and useful information from huge data; on the other hand, the 
verification of biological biomarkers requires large-scale association studies and pa-
tient samples, which requires countries and institutions building infrastructure, in or-
der to promote research cooperation and increase information sharing and 
knowledge creation opportunity. So, all levels of research institutions of the United 
States and the European Union are in the active construction of many different bi-
omarker databases, to effectively promote the sharing of knowledge in the field of 
biomarkers [Fan YL et al.,2013]. 
In the United States, the National Cancer Institute (NCI) has established a BMDB 
database to record all of its biomarkers. In the European Union, the European Med-
icines Agency's establish a public open electronic registry database (E-register), 
providing information on the availability, safety and effectiveness of drugs in clinical 
practice. In addition, South Korea, India, and other countries are also actively in-
volved in the construction of biological marker, for instance, the Indian contract re-
search organization (CRO) GVKBIO establish GOBIOM online biological markers 
database, containing more than 20 000 clinical biomarker information. From the per-
spective of the construction objectives and the role of this infrastructure, encourag-
ing cooperation between different projects and enhancing the link and sharing of the 
database will be the main trend of the future development of biomarkers [Fan YL et 
al.,2013]. 
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And in this study, is a process to find some special biomarkers: tumor biomarkers. 
Tumor biomarkers are the substance that tumor cells produced and released, often 
with antigen, enzyme, hormone metabolism exists in the form of tumor tissue or host 
body fluids, according to the biochemical and immunological characteristics can 
identify and diagnose the tumor. Although an elevated content of tumor marker may 
suggest the presence of cancer, only the level of tumor marker is not enough to 
diagnose cancer. Some tests, such as biopsies, also combined with a measure of 
tumor markers [Mishra et al.,2010].  
Recently, the scientists, who are in Swedish Karolinska Institute and Estonia center 
for medical technology, developed a new method for analysis of gene expression in 
collaboration, that is, discover and analyze the biomarker of the whole blood RNA-
SEQ [Kaarel Krjutskov et al.,2016]. Their findings are published in the "Reports Sci-
entific" magazine on August 12th, 2016. The cells carried by blood that can provide 
a variety of useful biomarkers. As a liquid biopsy, blood has been widely used in 
clinical research because of its simplicity of sampling and fast dynamics. Most of the 
cells are red blood cells that carry oxygen. Because of the high universality of globin, 
the study of blood-related gene expression biomarkers has become more compli-
cated, thus causing the technical deviation, and leaving behind the biological mole-
cules that cannot be detected. The first author, Dr. Kaarel Krjutškov (2016) said: " 
the decreased rate of globulin of Glob unlock is enough for any application. It has 
reduced the prevalence rate of the globulin from 63% to 5%, making it become an 
effective tool for biotech companies to add it to the kit." This new approach consists 
of a pair of short synthetic DNA chains, which can reticent the majority of the globulin 
RNA molecules, through highly specific combination. 
Compare the blood cells, is an efficient way to find an easily testable biomarker 
candidate. Blood testing is much easier than tissue detection. If the candidate gene 
overexpressed in blood cells, it may benefit the diagnosis of cancer. 
2.3 DNA microarray and the related database 
At the end of twentieth Century, with the development of biochemical technology, a 
new technology that can measure thousands mRNA expression of at the same time 
was born, under the impact of high-density chip production technology in the field of 
computer [Schena M et al., 1995]. Through these techniques, tens of thousands of 
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corresponding DNA probes can be placed on a chip of a few square centimeters, so 
as to simultaneously determine the expression of these genes in the sample [Müller 
HJ et al., 2004]. This technology is often called DNA microarray; GeneChip is only 
used to refer to a specific type of chip. The microarray is a member of the Biochips, 
but the most important one, other types of biochip includes protein chip, tissue chip, 
and so on. Compared with the traditional molecular biology and biochemistry exper-
iments that can only get a very limited data, Microarray can collectively get a lot of 
molecular biological data that are referred to as high-throughput technology. Using 
microarrays to represent high-throughput molecular biology technology allow scien-
tists to greatly enhance the ability of the access to experimental data, on which con-
tains thousands of gene expression values [Howe D et al., 2008]. On the one hand, 
this massive data provides the possibility to find more and more complex biological 
rules, on the other hand, it put forward unprecedented challenge of the data pro-
cessing and analysis technology. The traditional data analysis methods are inade-
quate, so a series of new adaptation of high-throughput biological data analysis and 
processing methods emerge as the times require, among them, image processing, 
pattern recognition, and machine learning play an important role. 
Basic principles of microarray are based on pairing principle of DNA, namely in the 
four nucleotides of adenine (A), thymine (T), guanine (G) and cytosine (C), A and T, 
G and C can respectively form a close pairing, which is basic mechanism of replica-
tion and transcription of DNA. The formation process of this pair is called hybridiza-
tion [E.M.Southern,1975]. Using this principle, we can use a specific DNA sequence 
as a probe to detect the presence and abundance of the paired DNA molecules. 
The microarray is fixed a large number of DNA probes in a very small area of the 
chip, hybridize nucleotide fragment with the corresponding probe, and then the cor-
responding gene expression could be obtained through the later treatment. Due to 
the small size of the chip, the conditions of the hybridization reaction between the 
probe and the sample can be ensured, and the detection of the expression of the 
gene can be quickly obtained by using a few samples. According to the different 
preparation and immobilization technology, the microarray is mainly divided into 
printed cDNA microarray and oligonucleotide microarray [Stefan Lorkowski et al., 
2003].  
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Figur 2.1 Probe sets in Affymetrix DNA microarray [ Stefan Lorkowski et al., 2003]. 
A gene chip can contain millions of probes, which are printed in a neat and orderly 
manner. A group of probes is derived from a gene, usually consisting of 20 pairs or 
11 pairs of probe sets, each of them is made up of mismatch (MM) and perfect 
match (MM), called the probe pair. The sequence of MM and PM is different from 
that of the central base, and the rest are consistent, as shown in figure 2.1. 
Microarray database is an important source for biomarkers discovery; researchers 
have established a number of specialized databases for the storage of microarray 
data related disease. As the main database resources of memory microarray, GEO 
(Gene Expression Omnibus) contains a wealthy microarray data related cancer. 
When querying "sapiens Homo" and "Cancer", it returns 278 data sets. In October 
2003, Daniel establishes the ONCOMINE database, especially collect cancer-
related microarray data sets, provide expression analysis of data mining and 
genome-scale on the web. In the version of ONCOMINE 3, the database contains 
264 gene expression datasets, more than 20 thousand samples of cancer tissue 
and normal tissue data [Rhodes D R et al., 2007]. Other microarray database in-
cludes Stanford gene microarray database (http://genome-www5.stanford.edu/Mi-
croArray/SMD), the EBI chip expression database (http://www.ebi.ac.uk/arrayex-
press), and MIT cancer genome project (http://www.broad.mit.edu/cancer/) and so 
on, all are an important resource for biomarker discovery. The microarray is capable 
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of recording the changes of thousands of genes of disease state under one-time. 
By comparing disease group and normal group of microarray data, find significant 
differences in the gene, which can be used to predict the related biomarkers. Due 
to the existence of a single chip data noise and system errors, the prediction results 
are often error [Autio R et al., 2009; Stafford P et al.,2007; Rhodes D R et al.,2004; 
Xu L et al., 2007]. Therefore, the latest research through the integration of different 
experimental sources of multiple microarray data, reduce the impact of the error in 
a single chip experiment, looking for more generic biomarkers and drug targets. The 
purpose of data integration is to process the data from different sources so that the 
data of the same gene can be compared with each other. 
The technology of gene expression by DNA microarray has been gradually replaced 
by RNA-seq technology. But after all, it has been more than 10 years of develop-
ment, and the global researcher data stored in the GEO or ArrayExpress database 
has been more than 50PB. Those enormous datasets are really very impressive, 
there are still a lot of waiting for the mining area. 
 
2.4 R and Bioconductor 
R language is an open source statistical computing and mapping language and is 
very similar to S language. The syntax of R is similar to other languages, and the 
function is very powerful. Bioconductor is an open source, open development soft-
ware based on R for the analysis of high-throughput genomic data, and the applica-
tion functionality of Bioconductor is presented in front of the user with the form of 
the integrated package [Hahne, F.et al., 2008]. It provides a variety of software pack-
ages, including a variety of genomic data analysis and annotation tools, most of 
which are targeted at DNA microarray or microarray data processing, analysis, 
annotation, and visualization. A large number of meta-data packages provide path-
way, organism, microarray and other annotations. The Bioconductor release version 
is updated twice a year [Gentleman, R. et al., 2005].  
The Bioconductor project started in 2001, the home page is http://www.bioconduc-
tor.org/. Bioconductor includes a number of package components that can be fully 
installed or be installed separately [Gentleman, R. et al., 2005]. In this study, the 
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data processing from download the dataset, analysis and calculate the expressions 
value are all used the Bioconductor package. 
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3 Materials and Methods                                                                                                                                                                                                                     
The ultimate goal of this study is to utilize the existing knowledge of signaling path-
way in the KEGG databases, and the analysis of the microarray datasets of GEO, 
to provide approaches and strategies to detect the potential tumor biomarkers. 
Four steps were undertaken in the following chapter: choosing the candidate genes 
from different pathway maps, choosing the suitable datasets, analyzing those data 
sets, comparing the candidate genes with the expression difference matrices. 
3.1 Choosing Candidate Genes  
The candidate genes were selected in cancer pathways or oncogene pathways from 
KEGG, by using the knowledge of biological signaling pathways and the function of 
oncogenes. 
A signaling pathway, is a series of chemical reactions which are initiated by a stim-
ulus (first messenger) acting on a receptor that is transduced to the cell interior 
through second messengers (which amplify the initial signal) and ultimately to effec-
tor molecules, resulting in a cell response to the initial stimulus [Bastien D et al., 
2009]. Those pathways in the cell are composed of a series of different proteins, 
which perform different physiological and biochemical functions. 
In molecular biology, the terms upstream and downstream can refer to the temporal 
and mechanistic order of cellular and molecular events. For example, in signal trans-
duction, the second messenger acts downstream to activation of cell membrane 
receptors. The other way around, activation of cell membrane receptors occurs up-
stream of the production of second messengers [Bastien D et al., 2009]. 
The regulation of the activity of the downstream protein (including activation or inhi-
bition) by the upstream protein in each signal pathway is mainly by adding or remov-
ing the phosphate group, in order to change the conformation of the downstream 
protein. Therefore, the main members of the signaling pathway are protein kinase 
and phosphatase, which can rapidly change and restore the conformation of the 
protein. It is not only a signal transduction process but also a process of cascade 
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amplification, from the cell receptor, received external signals to finally make a com-
prehensive response. Receptor protein translates extracellular signals into intracel-
lular signals via signaling cascade, dispersion, and adjustment, resulting in a series 
of cellular responses, including downstream regulation of gene expression, intracel-
lular enzyme activity changes, cytoskeleton configuration and synthesis of DNA 
change. These changes are not caused by one signal, but also can be produced by 
different combinations of different signals [Bradshaw et al., 2010].  
Oncogenes refer to a class of genes that are inherent in human or other animal cells 
(and oncogenic viruses). Also, known as the transforming genes, most of onco-
genes need an extra step, such as mutations in another gene, or environmental 
factors, such as viral infection, to cause cancer [Croce CM, 2008]. 
KEGG is a database resource for understanding high-level functions and utilities of 
the biological system, such as the cell, the organism, and the ecosystem, from mo-
lecular-level information, especially large-scale molecular datasets generated by 
genome sequencing and other high-throughput experimental technologies 
[Kanehisa M et al, 2000].  
At present,13 types of cancer pathways were integrated into KEGG pathway data-
base, every cancer pathway has its own complexity and heterogeneity. To analysis 
of every gene in every cancer, pathways seemed to be a tremendous work. It very 
useful to screen the pathway first, and selected the suitable candidate genes in sev-
eral types of cancer. 
In the following sections, some genes were collected from different types of cancer 
pathway and one oncogene pathway, also a noncancer-related pathway. The strat-
egy of how these genes were chosen and those pathways would be discussed in 
the following.  
3.1.1 Candidates selected from cancer pathway 
In cancer patients, some of the changes in gene expression, if they can be distin-
guished from ordinary healthy people, then these genes can be used as a potential 
tumor biomarker. So, these genes which would be selected are basically pathway 
downstream genes or a downstream gene which are directly activated by alterations 
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of an oncogene. By the cascade amplification through pathways, the enormous al-
teration of downstream genes would be expected.  
 
Figure 3.1 Pancreatic cancer pathway downloads from KEGG 
Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. 
When most investigators use the term 'pancreatic cancer' they are referring to pan-
creatic ductal adenocarcinoma (PDAC).  
From the view of Figure 3.1, the activated K-ras engages multiple effector pathways. 
Through a series of effects, until the gene NFKB1(also named “NFkB” in KEGG 
pathway map) affected DNA, and then blocked the apoptosis. So NFKB1 can also 
be regarded as an inhibitor gene of apoptosis. 
Oncogene pathways are always closely related to the occurrence of cancer, as in 
Pancreatic cancer pathway, also include Raf-MEK-MAPK signaling pathway. MAPK 
signaling pathway is a chain of proteins in the cell that communicates a signal from 
a receptor on the surface of the cell to the DNA in the nucleus of the cell. MAPK8 
would be chosen as a candidate gene, to the evaluation of this pathway, cause 
MAPK8 self-involved in the MAPK pathway, Further MAPK8 is a downstream gene 
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of the MAPK pathway. MAPK8 was also be funded in apoptotic pathway and other 
two cancer pathways. So is MAPK8 an Oncogene or a tumor suppressor gene, from 
the view of this pathway, that is unclear. In KEGG Database, MAPK8 also involved 
many different pathways, such as Non-alcoholic fatty liver disease, ErbB signaling 
pathway, Ras signaling pathway, Chagas disease (American trypanosomiasis), Shi-
gellosis, Salmonella infection and so on. MAPK8 has a very complex function. 
The change of oncogene and the downstream of an oncogene pathway were con-
sidered as the factors to choose the candidate genes in different cancer pathways. 
Clinical application of four different biomarkers, ER, PR, HER-2 and Ki-67, breast 
cancer can be divided into 4 molecular subtypes: luminal A subtype (ER-/PR-, 
Her2-), luminal B subtype (ER-/PR-, Her2-(+), Ki-67overexpression), HER2 positive 
(ER-, PR-, Her2+) and basal-like or triple negative breast cancer (ER-, PR-, Her2-) 
[Michael Gnant et al.,2011].   
 
Figure 3.2 Breast cancer pathway download from KEGG 
Notch1 and Notch4 overexpression will active the Notch signaling pathway, and this 
pathway is also highly related to cancer. HES1 and HEY gene as downstream genes 
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of Notch pathway ,was selected as a candidate gene for breast cancer, as shown in 
figure 3.2. 
In Thyroid Cancer pathway, it contents a signaling pathway PPAR, which is also 
very related to cancer, so its downstream gene, PPARG, was chosen as a candidate 
gene, shown in figure 3.3. 
 
Figure 3.3 Thyroid cancer pathway download from KEGG 
The genetic alterations of two oncogenes (β-catenin, Ras) was shown in Colorectal 
cancer pathway, the downstream genes of those two oncogenes are LEF1, BIRC5, 
MYC, CCND1, and FOS. Some of those 5 genes led to Anti-apoptosis, and some 
of them led to the proliferation. They are highly associated with the occurrence of 
cancer. So, those 5 genes were chosen as candidate biomarkers for colorectal can-
cer. 
3.1.2 Candidates selected from RAS pathway 
In this study of several cancer pathways, many are involved in RAS gene, as well 
as pathway MAPK. RAS signaling pathway is also highly related to cancer, thus 
several genes have also been selected in this pathway. 
Materials and Methods  17 
 
 
In 1982, American scientist R.A. Weinberg et al cloned the first human oncogene 
from bladder cancer cell, because murine sarcoma virus c-ras gene and it's previ-
ously found highly homologous, it is named as Ras gene (rat sarcoma) [Weinberg 
RA et al.,1982]. Ras gene is highly conserved in evolution, and it is widely used in 
all kinds of eukaryotic cells. The mammalian Ras protein family has three members, 
namely H-ras, K-ras and N-ras. Because the relative molecular weight of Ras pro-
tein is 21 kDa, it is also known as p21. Ras protein is localized on the inner side of 
the cell membrane, which is a GTP/GDP binding protein, which regulates the trans-
mission of signaling pathways through the transformation of GTP and GDP; After 
that, they found that the direct effect factor of Ras was Raf-1[Rapp UR et al.,1983], 
This links the Ras and ERK/MAPK signaling pathways. In higher organisms, the Raf 
serine / threonine kinase family consists of three members, A-raf, B-raf, and C-raf 
(also known as Ra-1).  
As the study progressed, the Ras signaling pathway constitutes a complex network. 
In brief, the tyrosine kinase receptor RTKs activated by growth factors is combined 
with GRB2 (growth factor receptor-bound protein 2) in a direct or indirect manner. 
GRB2 and receptor RTK after the recruitment of guanine nucleotide exchange factor 
SOS protein localized in the cell membrane adjacent to the Ras. In this way, SOS 
and Ras formed a complex, GTP instead of GDP and Ras combination, Ras was 
activated; And when GTP is hydrolyzed to Ras, GDP inactivation. Ras protein is 
activated to produce a series of cascade amplification reactions. First, it recruits the 
Raf1 protein to the cell membrane. After Raf kinase phosphorylation of MAPK ki-
nase (MAPKK, also known as MEK), then ERK1/2 (extracellular signal-regulated 
kinase, also known as MAPK) activated by MEK. When ERK is activated, it goes to 
the nucleus and activates the transcription factor to produce the corresponding bio-
logical effect [Lewis C et al.,2014]. 
18  Materials and Methods 
 
 
Figure 3.4 Schematic overview of the Ras/MAPK signaling pathway. This pathway started 
from external stimuli, through the ligand-activation of receptor tyrosine kinases, Ras, a small 
GTPase, was activated, by membrane-associated signaling complexes. Ras assist the het-
erodimerization and activation of Raf intracellular kinases, then Raf started a kinase cas-
cade through MEK and ERK. So the Ras/MAPK signaling pathway also called the Ras-Raf-
MEK-ERK pathway. By ERK drive the activation of transcription factors, that dysregulated 
cell cycle progression, proliferation, invasion, and survival. [Jennifer M Giltnane,2014]. 
In particular, the activation of Raf is not entirely dependent on Ras, and ERK can 
also be activated by other proteins other than Ras. This shows that every signal 
protein signaling cascade could be multiple upstream protein control, and they can 
also have a number of downstream target proteins, thus forming a complicated reg-
ulation network structure. With the development of the research of signal pathway, 
people began to study the mechanism of Ras signaling. In more than 60% of human 
malignant melanoma, B-raf mutations were found, and this mutation was found in 
some cancers of the rectum as well as in the thyroid and lung tumors [Curtin JA et 
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al.,2005]. After B-raf mutant, in some cases with C-raf to form a heterologous dimer, 
followed by a continuous activation of downstream of the ERK signal, and eventually 
the activation of protein kinase mTOR. The presence of Ras in tumor cells does not 
involve mutations in the Ras itself and the condition of persistent activation of the 
tumor itself. NF1 gene is the first discovery of tumor suppressor genes, it is a GAP 
protein (GTPase-activating protein). NF1 gene deletion mutations, due to the reduc-
tion of GTP hydrolysis and lead to the accumulation of GTP binding form of Ras 
protein, thereby enhancing the activity of Ras. In addition, reducing the expression 
of let-7 miRNA makes the target gene mRNA Ras increase, but also can improve 
the activity of Ras [McCubrey JA et al.,2007]. 
In RAS pathway, ETS1, KSR1 and PLA1A were selected as the downstream of the 
Ras-Raf-MEK-ERK pathway, the Ras-Raf-MEK-ERK pathway is part of the whole 
RAS pathway, as shown in Appendix 10. The Ras-Raf-MEK-ERK pathway is a 
highly related to cancer, and become the target of the cancer treatment [Hilger RA 
et al.,2002]. Also, one upstream gene of Raf1 were picked up as a reference. 
3.1.3 Candidates selected from related Pathway 
ELK1 is shared both by RAS pathway and GnRH pathway, it is also a downstream 
gene form MAPK signaling pathway. And in this position, there are two genes: Elk1 
and ETS.  Those genes are the part of many different pathways, ELK1 is also in-
volved in some cancer pathways, and there are some non-cancer pathways con-
tents this gene. Figure 3.5 shown that in GnRH signaling pathway also contains 
MAPK signaling pathway and RAS-Raf-1 pathway.  
GnRH (Gonadotropin-Releasing Hormone), which is synthesized in the hypothala-
mus, is a polypeptide hormone whose main function is to release the pituitary follicle 
stimulating hormone (FSH) and progesterone (LH). In mammals, GnRH-1 plays a 
role in the regulation of reproduction. The role of GnRH-2 in advanced mammals is 
mainly related to reproductive and sexual behavior [Ruf F et al., 2003]. This pathway 
was analyzed, that assumed some potential biomarkers for prostate cancer or 
breast cancer would be funded. 
In other pathways, that ELK1 also associated with, either The Ras pathway and 
MAPK pathway are not show up together, or they are more complex than GnRH 
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pathway, the study of those pathways are time-consuming and may be less related 
to cancer than GnRH pathway. 
ETS was selected as a candidate gene from RAS pathway, and for the gene ELK1, 
some genes were picked up from GnRH pathway instead. In this work, only one 
ELK1 related pathway was chosen, to evaluation those genes in this pathway, to 
see if there are some genes suitable for cancer biomarkers. Maybe for the further 
work, the complexes pathway can be chosen for a larger work. In the GnRH pathway, 
the approach to choosing the candidate genes is different with the other pathways. 
Cause in this pathway there is no changing oncogenes and the downstream gene 
from MAPK signaling pathway and Ras pathway are already collected of the former 
selection. Therefore in this map, five genes were selected, three genes (GNRHR, 
MMP14, CACN) are located on the cell surface. The downstream genes of BMK and 
Pyk2 are not indicated in GnRH signaling pathway, shown in figure 3.5. If those two 
genes play any roles in cancer occurrence, will be detected in the next process. 
 
Figure 3.5 GnRH signaling pathway downloads from KEGG 
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3.2 Selected Candidate Genes 
Altogether 27 genes were considered to be candidate biomarkers, the summary of 
those genes shown in Table 3.1. Many of those candidates were chosen as down-
stream genes from cancer-related pathways (like RAS or MAPK etc.) and the onco-
genes alterations, those are the main way to selected genes from cancer pathways: 
like LEF1, FOS, MYC, HEY1, ETS1 etc. Cause of the signaling cascades amplifica-
tion, tremendous changes of gene expression date will be expected in those candi-
dates between cancer patients and healthy individuals. Some of them were chosen 
because of their ability of inhibition of apoptotic: like FOX01, CREB3, NFKB1. Some 
genes selected from GnRH signaling pathway, the cause of their location on the cell 
surface, it will be easily detectable and as a very effective for the drug target. The 
genes on the cell surface in other cancer pathways, like Her-2, KIT, and EFGR etc. 
were already used as cancer biomarkers [Table of Pharmacogenomic Biomarkers 
in Drug Labeling,2016]. and some others like GFR, TRK etc. either contain many 
other cancer pathways in KEGG or their function and the biological role was already 
studied [Eggert A et al., 2000]. 
 
Table 3.1 the candidate genes from different pathways 
3.3 Collection of Datasets 
This section summarizes the datasets that were chosen and used to detect the po-
tential of candidate genes as cancer biomarkers. These potentials were measured 
as the following: whether those genes have expression difference between cancer 
patients and healthy individuals. Those DNA microarray datasets were chosen ac-
cording to this purpose. There are expression differences compared between nor-
mal Tissue from healthy individuals and tumor tissue from cancer patients, some 
blood cells on the analysis of different tumors were also chosen. Nine different can-
cer types were chosen to analyses. Because 18 candidate genes were selected 
from 5 cancer types pathways, so those 5 types datasets were chosen at first, and 
the sample were all from a different tissue. Some other cancer types were chosen 
Prostate cancer Thyroid cancer Pancreatic cancer Colorectal cancer Breast cancer RAS pathway GnRH signaling Pathway
FOX01(2308) PPARG(5468) NFKB1(4790) BIRC5(332) FLT4(2324) SHOC2(8036) GNRHR(2798)
MTOR(2475) RXRA(6256) MAPK8(5599) LEF1(51176) HEY1(23462) KSR1(8844) CACNA1C(775)
CREB3(10488) TGFB1(7040) CCND1(595) HES1(3280)  PLA1A(51365) MMP14(4323)
HSP90AA1(3320) FOS(2353) HES5(388585) ETS1(2113) PTK2B(2185)
MYC(4609) MAPK7(5598)
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as additional, 3 of those data sets were collected, whose sample were gathered 
from blood cells: PBMC and Primary human monocytes. 
 
Table 3.2 the microarray datasets from GEO 
As shown in Table 3.2, those datasets are from the same platform U133 Plus 2.0, 
to reduce the sample bias caused of crossed platforms. 
3.4 Data Processing 
This section demonstrates the use of Bioconductor in the analysis of Microarray 
datasets: from download to the gene expression profiling. 
3.4.1 Data Pretreatment 
The microarray analysis is performing by R language of using different packages 
from Bioconductor. In order to perform the analysis, the first step is downloading 
each dataset by GEOquery package. Then the dataset would be compared with 
them. 
There are two different way to use the package GEOquery: man can either down-
load the data that has been pre-processed by providers, or the raw data from GEO. 
The pre-processed datasets were downloaded at first, by using very simple codes 
and few minutes, the first brief review can be made as follow. With drowning a box-
plot like a figure 3.6. The difference between the two datasets was shown directly: 
the center lines of each chip of dataset GSE 26910 are basically in a line, and in 
dataset GSE3678, the central line of the first two chips (GMS85222, GMS85223) 
are not in a line. And the expression value of GSE 26910 were dueled with log 2, 
but GSE3678 were not. So, the expression value of GSE 26910 is between 2 and 
8. The GSE3678 is up to near 200. 
ID  platform Information Normal Tumor Tissue
GSE26910 U133 Plus 2.0 Prostate tumor 6 6 Prostate
GSE26910 U133 Plus 2.0 Breast tumor 6 6 Breast
GSE49515 U133 Plus 2.0 Gastric cancer 3 10 PBMC
GSE32323 U133 Plus 2.0 Colorectal cancer 17 17 Colorectal
GSE3678 U133 Plus 2.0 thyroid tumor 7 7 Thyroid
GSE18842 U133 Plus 2.0 NSC lung tumor 45 46 Lung
GSE49515 U133 Plus 2.0 HCC cancer 10 10 PBMC
GSE65517 U133 Plus 2.0 Metastatic Breast tumor 4 3 Primary human monocytes
GSE16515 U133 Plus 2.0 Pancreatic cancer 36 14 Pancreatic
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Figure 3.6 Two Boxplot of GSE26910 breast sample (lift) and GSE3678(right). The X axis 
represents the Chips name; The Y axis represents the expression value. 6 breast cancer 
samples and 6 healthy samples were included in the GSE26910 datasets. In GSE3678 
dataset content 7 cancer samples and 7 normal samples. 
 
Figure 3.7 Boxplot of GSE18842 
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As shown in Figure 3.7, the central line of the chips GSM467031 and GSM467033 
are not in a line, as well as GSM466973 and GSM466975. The expression value of 
dataset GSE18842 is also transformed with log 2. 
As a brief review from this section, the data sets cannot directly be used, they 
weren’t used the appropriate normalizations method, and GSE3678 was not used 
log2 deformation. The proposal of build the expression difference matrices must 
begin with the row data. 
In the following sections, the dataset GSE18842 would be used as an example to 
evaluate and integrate. To analyze the dataset, a quality control should be done. 
For this Microarray, I used the R code “image (data [,1])” to see the chip grayscale 
map of the first chip, shown in figure 3.8. In the upper left corner, would be the Chips 
name on it, and depends on we see the name or not can help us to understand if 
the chip data is reliable. 
 
Figure 3.8 grayscale map of the first chip of GSE18842. 
A simple evaluation method is better than the direct image method, which is based 
on several average evaluations. A common feature of these methods Is to assume 
that a set of experiments in each of the chip data for an average value of the indi-
cators are not quite different. Affymetrix company described in detail these stand-
ards in the guide manual [User Guide, 2012], and They are:  
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1. Scaling factor: The average value of all probes on each chip is used to determine 
the scale factor. Assuming the chip expression values ranged from 0 to 200, the 
average value is 100. If there are two chips to the comparison, the first chip 
average value is 50, second chip value is 200 so their scaling factor is 2 (50/100) 
and 0.5 (100/50). In accordance with the standards of Affymetrix, the scale factor 
for comparison between the chips must be less than 3 [User Guide, 2012], Under 
this assumption, 2/0.5 is equal to 4, is greater than 3, so these two chips cannot 
be used for comparison. 
2. Detection call and Percent present: A set of probes can be detected: Present, 
Absent, and Marginal present. 
3. Average background: For each chip, according to all the MM values (chapter 
2.3), the average value of background noise can be obtained, so does the Mini-
mum and maximum values.  
4. Internal control genes: mRNA is degraded from the 5 ′ end to 3'end, chip probe 
group is also designed according to this order, So the measurement results of 
the probe group can be reflected in this trend. Because most cells contain ß-
actin and GAPDH genes, they are chosen as Internal control genes set in Affy-
metrix chips, to observe the degradation degree of RNA. The probe groups for 
these two genes are well covered from their 3’ end to the 5’ end. Using the divi-
sion of the signal intensity between 3’ end and 5’ end can be a good indicator of 
the quality of the experiment. Affymetrix suggested the threshold of actin3/actin5 
is less than 3, gapdh3/gapdh5 is less than 1.25. 
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Figure 3.9 A quality control chart of the part of GSE18842. 
As shown in the figure 3.9, from lift to right: the first column is the name of the chips, 
there are two numbers for each chip on the second column, the number above is 
percent present, and the number under is average background, the third column is 
coordinate of the scaling factor and graph 3’/5’ and actin 3’/5’. The blue solid circle 
is a scaling factor; the triangle presented actin 3’/5’. For a full view of datasets, 
GSE18842 is presented in Appendix 9. In order to facilitate the explanation of those 
indexes, I chose 4 chips of GSE18842 data sets to drown this quality control chart. 
When all the three indexes are blue, then this data sets is up to standard. One red 
index is not assumed that the experiment is failed, but if all indexes of the same chip 
are abnormal, that means this chip is useless. From the view of this QC chart, there 
are some red indexes of some chips, but those chips have also blue indexes. The 
absolute value of scaling factors of all the chips are under 3, and either chip has all 
abnormal indexes. It is hard to decide, whether those chips are all good to use or 
not. So, the further study will take in the following. 
RNA degradation is an important factor that affects the quality of the micorarray data. 
Because the RNA is from 5' end to degrading, So the fluorescence intensity of the 
probe 5'end, in theory, should be lower than that of the 3' end. The slope of the RNA 
degradation curve shows the trend, the smaller the slope, the less of the degradation; 
On the contrary, the more degradation. However, if the slope is too small, or even 
close to 0, we should pay special attention to, This does not represent no 
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degradation of RNA sample, and may all the RNA were degraded. Because, in the 
actual experiment, no degradation of RNA is not possible, It may be because the 
degradation of RNA is too serious, it leads to the calculated value of close to 0. 
 
Figur 3.10 RNA degradation plot of each chip in datasets GSE18842. This plot shows that 
The slope of the RNA degradation curve is slightly rose from 5’ to 3’.  
All chips of datasets GSE18842 have indicated trends, that can be seeing in the 
figure 3.10, the RNA sample during the chip experiment degraded from 5’ end. 
Section 3.4.1 illustrates the quality control with GSE18842 as an example. The other 
datasets that selected, would all through this processes to assess, whether they are 
suitable for next statistical analysis.   
3.4.2 Data Integration 
After evaluation and selection, those datasets need to be preprocessed, before the 
expression matrices were established. Use the integration algorithm, those data 
sets will achieve both background control and normalization. In the Bioconductor 
package, there are about three kinds of integration algorithms: dChip, MAS5 and 
RMA. However, in practical work, the MAS5 and RMA algorithm are more frequently 
used than dChip. Because the dChip is a not-open source, and not integrated by 
Bioconductor. The differences between MAS5 and RMA algorithm, are discussed in 
the following: 
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 Each chip can separately use MAS5 to accomplish the normalization, RMA 
is used multi-chip model, all the chips need to be normalized at once. 
 MAS5 using MM (chapter 2.3) probe information to remove background noise, 
the basic idea is PM-MM, RMA does not apply MM information, but PM based on 
the signal distribution using a random model to estimate the expression. 
 RMA processing data is into log2 conversion, and MAS5 is not, this is very 
important because a lot of chip analysis software or function needs of the input data 
must be converted to a log2. 
By drawing the signal strength distribution graph and the box line graph, we can 
compare the different algorithms. 
From the point of view of the signal intensity distribution, the MAS5 algorithm has a 
lot of negative numbers, and the curves are not coincident with each other. The 
original does not coincide with the multiple distribution curves after used the RMA 
algorithm are a coincidence in the together. If the gcRMA algorithm is used, not only 
all the curves are well coincident, but also their distribution is more similar to Gauss 
distribution. Therefore, the gcRMA algorithm to improve the RMA performance in 
this group of the dataset is very obvious. However, this does not mean that the 
gcRMA algorithm is always better than the RMA algorithm, for different data, need 
to compare the algorithm, in order to further determine which algorithm is the most 
suitable. 
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Figur 3.11 Histogram of Signal intensity, All the curves are well coincident though the 
gcRMA model. 
In contrast experiment, the even comparison between the experimental group and 
the control group, The expression value of most genes should be consistent. This 
standard is used to appraisal of the normalization. Figur 3.11 illustrates that, though 
the integration with gcRMA, all the curven stayed nearly with each other, these 
datasets performance the best quality for statistic analysis.  
In the next few sections,a special diagram, MA plot diagram will be discussed in the 
following. 
An MA plot, full name: The distribution of the red/green intensity ratio plotted by the 
average intensity, is an application of a Bland–Altman plot for a optical 
representation of two-channel DNA microarray gene expression data which has 
been converted onto the M (log ratios) and A (mean average) scale. Microarray data 
is often normalized within chips to control for systematic biases in dye coupling and 
hybridization efficiencies, as well as other technical bases in the DNA probes and 
the print tip used to spot the chip[YH Yang et al., 2002]. To determine whether 
normalization is required, one can plot Cy5 (R) intensities against Cy3 (G) intensities 
and see whether the incline of the line is around 1. An improved method, which is 
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basically a scaled, 45-degree rotation of the R vs. G plot is an MA-plot.[Dudoit S et 
al.,2002]. The MA-plot is a plot of the distribution of the red/green intensity ratio ('M') 
plotted by the average intensity ('A'). M and A are defined by the following equations. 
  𝑀 = log2(𝑅/𝐺)                                                                                                   (3.1) 
A = 
1
2
∗ log2(𝑅 ∗ 𝐺)                                                                                              (3.2) 
Where the R is plot Cy5 (Red) intensities,and G is plot Cy3 (G) intensities. For the 
signal channel microarrays, The gene expression value is related to the intensity of 
a single signal, then the R and G can be replaced with the expression value from 
one and another chip. 
In many microarray gene expression experiments, a fundamental assumption is that 
most of the genes would not see any change in their expression, therefore, the 
majority of the points on the y-axis (M) would be located at 0 since Log(1) is 0. If this 
is not the state, then a normalization method should be applied to the data before 
statistical analysis. 
And in this study, all data sets were chosen from the platform U133 plus 2.0, this is 
a one channel DNA microarray platform. In this platform, R and G are not the 
red/green intensity ratio, their R and G represented the value from the two compared 
chips. Like figure 3.12 and figure 3.13, the GSM466947, GSM466948, GSM466949, 
GSM466950 from GSE18842 were compared between every two chips, before and 
after normalization. 
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Figure 3.12 MA plot with original data of GSE18842.The red line is not overlapped with the 
0 line, the Median of each MA plot are not 0. 
 
Figure 3.13 MA plot used gcRMA data. After used gcRMA model, the red line overlapped 
the 0 line, and all the median are 0. 
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For the dataset GSE18842, gcRMA method was used to carry out the background 
correction and normalization. The same analysis was also used for the other data 
sets,and also gcRMA method was chosen for the background correction and 
normalization of all the data set. That doesn’t mean that gcRMA is always better 
than other two methods.  
The reason ,why gcRMA were chosen as the integration method is that this method 
is better than MAS5.0 in most of the datasets, it is only a little change between RMA 
and gcRMA, shown in figure 3.11: a blue curve in RMA model is not good coincident 
with other curves. RMA and gcRMA are both with log2 conversion, are ready for the 
limma package, gcRMA is a derivative of RMA, and shown a little better than RMA 
in many data sets. After all data sets were analyzed with the same process, that 
ruled before, all the data sets were integrated with gcRMA model. 
3.4.3 Build Expression Difference Matrices 
After the integrated of all those data sets, all the samples in those datasets were 
divided. Some data sets have a variety of cancer and negative control, the data set 
has also been split into a number of groups. According to different objects of different 
data sets, those data were divided into cancer group and normal group. Then those 
datasets were according to different types of cancer respectively analyzed. Limma 
packet was used to do the analysis and calculation of those datasets. Limma packet 
is a comprehensive software package, that based on R and Bioconductor ,used for 
the analysis of microarray data. This package features a complete, high rate of use, 
has become a synonym for the process of microarray data processing[Smyth,G, 
2004]. The main design of Limma application is as following : the experimental 
matrix, linear simulation, Bayes test and generate the results of the report. 
The differential expression matrix was produced as a result for each type of cancer 
datasets. This is the final result of transpose into EXCEL form. 
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Table 3.3 An example of expression difference Matrix of dataset GSE26910, and they are 
sorted with the value of adj.P.Val. 
 As shown in the Table 3.3, The first and second columns in the table of "ID" is a 
probe group of Affymetrix ID, the third column is the "adj.P.Value" is to adjust the P 
value, the fourth column is the "P.Value" is the Bayes test to obtain the value of P, 
the fifth column "t" is “t value “used Bayes test after the adjustment of the two groups 
of expression values of T test. Sixth column "B" is the empirical Bayes test to get 
the standard deviation of the logarithm value. The seventh column of” logFC” is the 
two group of expression values to 2 for the background of the change of multiple, 
because, before the use of limma packet, all the data are carried out with log2, so 
here is actually just the difference between the value of the two groups of gene 
expression. And the rest of the columns are “Gene ID”,” Gene symbol”. 
Fold change (FC) was first applied to the analysis of microarray data. This method 
is based on the ratio value of the gene chip from large to small sort, Ratio is the ratio 
of cy3/cy5, also known as R/G value. There was no significant difference in the ex-
pression of genes in the 0.5-2.0 range, but the expression of the gene was signifi-
cantly changed. Due to the different experimental conditions, this threshold range 
will be adjusted according to the confidence interval [Gerhold D et al.,2001; Mutch 
DM et al.,2002]. The advantage of this method is that the need of the chip is less, 
and the research cost is saved; the disadvantage is that the conclusion is too simple. 
ID adj.P.Val P.Value t B logFC Gene.ID Gene.symbol
219059_s_at 219059_s_at 0,04422383 8,21E-07 17,7423179 3,82239309 4,39090333 10894 LYVE1
209774_x_at 209774_x_at 0,04422383 1,62E-06 15,9747411 3,60341869 3,58809 2920 CXCL2
203980_at 203980_at 0,04436285 2,43E-06 14,9923376 3,45546291 4,83247 2167 FABP4
236383_at 236383_at 0,04804228 4,49E-06 13,6277876 3,20999258 4,29079667
209189_at 209189_at 0,04804228 5,06E-06 13,3738356 3,1582775 3,29689333 2353 FOS
232541_at 232541_at 0,04804228 5,27E-06 13,2887115 3,14047121 3,75169
1552509_a_at1552509_a_at 0,08688237 1,11E-05 11,8164793 2,7902233 4,18646 146894 CD300LG
221841_s_at 221841_s_at 0,09242166 1,46E-05 11,3206657 2,65161462 5,20933667 9314 KLF4
213900_at 213900_at 0,09242166 1,64E-05 11,1090749 2,5888033 2,98721333 9413 FAM189A2
209555_s_at 209555_s_at 0,09242166 1,71E-05 11,0397841 2,56773255 4,47852 948 CD36
203910_at 203910_at 0,09242166 1,86E-05 10,8923901 2,52206361 2,29612667 9411 ARHGAP29
235489_at 235489_at 0,09573757 2,22E-05 10,5857548 2,42322349 2,29777667 57381 RHOJ
231181_at 231181_at 0,09573757 2,28E-05 10,5469527 2,41033446 4,14069667
233261_at 233261_at 0,1276125 3,57E-05 9,81371094 2,14938818 2,79773 1879 EBF1
219064_at 219064_at 0,1276125 3,74E-05 9,74027917 2,12132564 2,29117 80760 ITIH5
232165_at 232165_at 0,1276125 3,89E-05 -9,6785012 2,09742775 -3,0035733 83481 EPPK1
206030_at 206030_at 0,1276125 4,03E-05 9,62256778 2,07555986 4,49244 443 ASPA
242541_at 242541_at 0,1276125 4,37E-05 9,49816677 2,02612365 2,25247 10350 ABCA9
242197_x_at 242197_x_at 0,1276125 4,43E-05 9,47669267 2,01747665 3,55083 948 CD36
204482_at 204482_at 0,12878851 4,87E-05 9,33472676 1,9594546 3,13267 7122 CLDN5
1569607_s_at1569607_s_at 0,12878851 4,95E-05 9,3108457 1,94954617 3,87567333 102725051///102723891///728747///441430///441425///440482///391267///284232///84210LOC102725051///LOC102723891///ANKRD20A4 /ANKRD20A2///ANKRD20A3///ANKRD20A5P///ANKRD20A11P///ANKRD20A9P///ANKRD20A1
228770_at 228770_at 0,12913562 5,20E-05 9,23697953 1,91862387 2,92304 115330 GPR146
206742_at 206742_at 0,13096558 5,51E-05 9,1498037 1,88158872 5,65017 100532742///2277PIR-FIGF///FIGF
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By using limma package, the Fold change(FC) is presented as logFC in the expres-
sion difference matrices.  
In this study, adj.P.Value was used though Benjamini & Hochberg’ model. this so 
called False discovery rate. The false discovery rate (FDR) is one way of conceptu-
alizing the rate of type I errors in null hypothesis testing when conducting multiple 
comparisons [Benjamini et al.,1995]. 
In this work, the potential cancer biomarkers should be easily detectable, therefore, 
a highly diverse between cancer patients to healthy individually is required. That 
means those candidates must have the obvious difference in gene expression. Thus 
the threshold of the absolute value of log FC was set to 1.5, P value and adj.P.Value 
is 0.05. 
For all the differences in expression matrix, 27 candidate genes were checked in 
the output expression matrix and used the threshold value that Mentioned above. 
To find out whether they have differences in expression between cancer group and 
healthy group. If a gene candidate has an absolute value of logFC bigger than 1.5, 
and P.value and adj. P.Value is smaller than 0.05, this candidate gene was differ-
entially expressed gene between cancer and normal sample. 
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4 Result 
Altogether, 27 genes were analyzed in different expression matrices. First, the dif-
ferentially expressed genes were found in the following table 4.1. 
 
Table 4.1 Differentially expressed genes marked by different datasets, the blue type of the 
value indicating the positive value of logFC, and the red type of the value indicating negative 
logFC value. * means either P value or adj. P.Value is larger than 0.05. 
 As my design of expression matrix, the negative value of logFC means this gene is 
upregulated in the tumor sample. And the original expression value of those differ-
entially expressed genes were all checked, the histogram of them was shown in the 
appendix1-7. 
CCND1, BIRC5, MYC, MPP14, and PLA1A are overexpressed in many types of 
cancer patients and have the potential to be tumor biomarkers for the different uses. 
PPARG, FOS, HES1, PLA1A, MAPK7 are low expressed in some type of cancer 
patients, their usage for potential tumor biomarkers are the patterns of gene expres-
sion. Low expression of PPARG, FOS, PLA1A may be considered as an indicator 
candidates Prostate Breast Colorectal Gastric Thyroid HCC  NSC Lung Breast M1 Pancreatic
FOX01(2308) 0,701 0,727 0,993 -0,467 0,736 0,616 0,624 -0,305 0,215
MTOR(2475) 0,103 0,305 -0,121 0,049 -0,124 0,008 -0,296 -0,291 -0,031
CREB3(10488) 0,454 -0,829 0,511 0,361 0,132 0,094 -0,004 0,091 0,106
HSP90AA1(3320) -0,141 0,767 -0,228 -0,475 -0,254 0,165 -0,153 0,091 -0,044
PPARG(5468) 1,296 *2,116 0,384 0,171 0,325 0,052 2,199 NA 0,765
RXRA(6256) -0,361 -0,231 0,376 0,573 0,343 -0,082 0,541 -0,109 0,051
TP53(7157) -0,214 0,035 -0,195 0,419 -0,26 -0,934 -0,619 -0,76 0,468
NFKB1(4790) 0,242 0,241 0,132 0,151 -0,065 -0,962 0,411 -0,156 -0,075
MAPK8(5599) 0,046 -0,564 -0,187 0,062 0,089 0,273 0,057 0,345 -0,069
TGFB1(7040) 0,017 -0,271 0,041 0,003 -0,39 -0,012 0,012 0,029 0,043
LEF1(51176) -0,344 -0,187 -0,693 -0,767 -0,209 -0,008 -1,492 -0,026 0,037
FOS(2353) -0,051 3,297 1,426 -1,093 1,837 -0,048 2,221 0,233 0,255
MYC(4609) 0,627 *2,452 -2,931 0,783 0,607 -0,786 0,002 0,492 -0,216
BIRC5(332) -0,317 -1,488 -0,633 0,993 -0,249 -0,383 -3,976 -1,371 0,254
CCND1(595) 0,741 -0,672 -0,894 0,931 0,636 -0,512 0,205 -4,527 -0,131
FLT4(2324) -0,111 1,107 0,164 -0,163 0,159 0,021 0,547 1,263 0,159
HEY1(23462) 0,427 -1,079 0,361 0,022 -0,129 0,008 0,065 0,224 0,243
HES1(3280) -0,121 0,371 0,051 0,023 -0,203 0,034 -0,131 2,329 0,118
HES5(388585) -0,243 -0,302 0,124 0,0202 -0,371 0,016 -0,891 NA 0,072
SHOC2(8036) 0,166 -0,045 0,813 -0,042 0,166 -0,168 0,306 -0,509 0,092
KSR1(8844) -0,192 -0,301 0,544 0,403 0,013 0,193 0,302 0,369 -0,013
 PLA1A(51365) -3,521 -0,241 0,223 0,014 1,151 0,052 1,993 2,32 0,009
ETS1(2113) -0,551 0,791 0,043 0,021 0,188 -0,388 1,073 0,936 0,161
GNRHR(2798) -0,401 0,163 0,023 -0,011 0,132 -0,021 0,079 NA -0,008
MMP14(4323) -0,124 -1,312 0,016 -0,006 -0,355 0,371 -1,628 -0,567 -0,146
PTK2B(2185) 0,086 -0,186 1,183 0,212 0,482 0,041 0,548 -0,095 0,092
MAPK7(5598) 0,789 -0,361 0,663 0,943 0,046 0,71 0,226 1,779 0,071
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for NSC lung cancer, low expressed HES1, PLA1A and MAPK7 may be used to 
detect the metastasis of breast cancer, FOS also has the potential as a biomarker 
for breast and Thyroid cancer. 
Because most tumor markers are produced at much higher levels in cancerous con-
ditions. Therefore, the potential of the five overexpressed genes will be discussed 
emphasis. 
4.1 Candidate Biomarkers 
Cyclin-D1 protein plays an important part in the progress of the cells in the cell cycle 
G1 phase. Cyclin-D1 protein gene, CCND1 amplification in about 20% of breast 
cancer, this protein is over-expression in about 50% of cases. This led to determine 
the further research of cycle D1 protein as a biomarker in breast cancer; However, 
according to the clinical work, it hasn’t approved as a biomarker in use [Barnes DM 
1998].  
Survivin also called BIRC5 is found by Altieri, et al. in 1997, is the IAP (inhibitor of 
apoptosis of protein) members of the family, is composed of 142 amino acids of 
relative molecular mass of 16. 5 x 103 protein. Survivin is known to be expressed 
during fetal development and across most tumor cell types but is rarely extend in 
normal, non-malignant adult cells [Altieri DC et al.,1997]. Tamm et al. showed that 
overexpression of survivin has been reported in various human malignancies, al-
most all cancers have choice survivin expression profile compared to normal tissues 
[Tamm I et al., 1998]. The strategies of targeting survivin network have entered in 
the clinical trials in humans [Altieri DC et al., 2006].   
Myc (c-Myc/ v-myc avian myelocytomatosis viral oncogene homolog) is a regulator 
gene that codes for a transcription factor. The protein encoded by this gene is a 
multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, 
apoptosis and cellular transformation [Myc. NCBI]. At present, the Myc gene mark-
ers are already used in the judgment of tumor and recurrence and metastasis [Gon-
zalez RM et al., 2011; Hassanein M et al.,2012; Zhu D et al.,2014]. 
MMP14 (also known as MT1 MMP) is a membrane type of matrix metalloprotein-
ases (MMPs), it was reported excesses expression in a wide variety of tumor cell 
surface, it can degrade extracellular matrix of ingredients and can activate MMP2 
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and MMP13, is considered to be the key enzyme of tumor invasion and metastasis. 
MMP14 inhibitors have become the research focus, to develop a specific inhibitor 
of MMP14 for cancer treatment is very significantly [Bowen Tan, 2001].  
Lucia Sepiashvili et al. has studied the potential of MMP14 as a tumor biomarker for 
head and neck squamous cell carcinoma [Lusia Sepiashvili et al., 2012]. For the 
following research, their discovery strategy can be also used to detect the potential 
of MMP14 as a biomarker for NSC lung cancer. 
There is no clear evidence that PLA1A is directly related to the occurrence of pros-
tate cancer. According to the research of Scott A. Tomlins et al., PLA1A was identi-
fied as direct targets of TMPRSS2/ERG gene fusions [Scott A et al., 2008]. The 
previous studies on TMPRSS2/ERG gene fusions showed that, TMPRSS2-ERG fu-
sion gene is the most frequent, present in 40% - 80% of prostate cancers in humans, 
depending on the clinical stage [Wang J et al.,2006; Cerveira N et al., 2006; Clark J 
et al., 2007; Perner S et al.,2006; Yoshimoto M et al.,2006; Rajput AB et al., 2007; 
Mehra R et al., 2007; Nam RK et al.,2007; Lapointe J et al.,2007; Demichelis F et 
al.,2007; Soller MJ et al.,2006; Attard G et al.,2008]. PLA1A overexpression in pros-
tate cancer sample has the potential for representation on TMPRSS2/ERG gene 
fusions of prostate cancer. 
4.2 Further Study of MMPs and PLA1A 
Matrix metalloproteases (MMPs), also known as matrixins, are a multigene family 
of zinc-dependent endopeptidases that share a similar structure and they all have 
the capacity to degrade virtually every component of the extracellular matrix (ECM) 
[Verma RP et al.,2007].The matrix metalloproteinase (MMP) family of extracellular 
proteinases have long been associated with cancer invasion and metastasis by vir-
tue of their ability to collectively degrade all components of the extracellular matrix 
(ECM) [Michelle D et al.,2007]. 
Using the expression difference matrix, that established in this study, a preliminary 
study of MMPs as a tumor biomarker can be presented in Table 5.1 
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Table 4.2 The potential of MMPs as tumor biomarkers used the expression different matrix  
In this table 4.2 is shown that MMPs has a variety potential as tumor biomarkers. 
For example, MMP1, MMP3, and MMP7 can choose to be the biomarkers for colo-
rectal cancer. For thyroid cancer, MMP7 and MMP16 both have the potential to be 
tumor biomarkers. For NSC lung cancer, MMP1, MMP13, MMP3, MMP10, MMP11, 
MMP12, MMP14 can be used as potential tumor biomarkers for the future study. 
MMP8, MMP9, MMP25, MMP20, MMP23 can be considered as potential bi-
omarkers for metastasis breast cancer. The MMPs family is one of the most im-
portant regulatory molecules in the process of tumor invasion and metastasis. so 
the understanding of the role of each MMPs of cancer metastasis may show the 
potential biomarkers for the cancer metastasis. 
For the applications of MMPs in human cancers are as potential tumor biomarkers 
for diagnostic and prognostic. I have collected some of the studies, that analyzed 
the potential of MMPs as tumor biomarkers and compared with this study, shown in 
table 4.3 in the following. 
 
 
 
 
Candidates Prostate Breast Colorectal Gastric Thyroid HCC  NSC Lung Breast M1 Pancreatic
Collagenases MMP1 √ √
MMP8 √
MMP13 √
MMp18
Gelatinases MMP2
MMP9 √ √
Stromelysins MMP3 √ √
MMP10 √
Stromelysin like MMPsM P11 √
MMP12 √
Matrilysins MMP7 √ √
MMP26
Membrane type MMPsM P14 √
MMP15
MMP16 √
MMP17
MMP24
MMP25 √
Other MMPs MMP19
MMP20 √
MMP21
MMP22
MMP23 √
MMP27
MMP28 √
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Cancer type and MMPs (former 
studies) 
Detected in Tissue/Body 
Fluid 
Method of Analysis Cancer type and MMPs 
(this study) 
Breast 
MMP13 [Zhang B et al.,2008] 
MMP9  [Wu ZS et al., 2008;         
             Fernandez CA et al.,2005;   
Ranuncolo SM et al.,2003]  
MMP1 [Poola I et al., 2005] 
 
Tissue 
Urine, serum, plasma, tis-
sue 
 
Tissue, nipple aspirates 
 
IHC 
ELISA, IHC, Gelatin zymo-
graphy 
 
Gene analysis 
Breast (metastasis) 
MMP8  
MMP9  
MMP25  
MMP20  
MMP23 
Lung 
MMP9 [Jumper C et al.,2004] 
 
MMP7 [Liu D et al.,2007] 
MMP1 [Su L et al., 2005;              
Sauter W et al.,2008] 
 
Serum, bronchial   lavage 
 
Tissue 
Tissue 
 
ELISA 
 
IHC 
Gene analysis 
Lung (NSC) 
MMP1,  
MMP13,  
MMP3,  
MMP10,  
MMP11,  
MMP12,  
MMP14 
Colorectal 
MMP2 [Hilska M et al.,2007;            
Langenskiold M et al.,2005; 
Tutton MG et al., 2003] 
MMP9 [Cho YB et al., 2007] 
MMP7 [Maurel J et al.,2007] 
MMP13 [Leeman MF et al.,2002] 
MMP1 [Baker EA et al.,2003] 
 
Tissue, plasma 
 
 
Tissue 
Serum 
Tissue 
Tissue 
 
IHC, ELISA 
 
 
IHC 
ELISA 
Gelatin zymography 
ELISA 
Colorectal 
MMP1,  
MMP3  
MMP7 
Table 4.3 A comparison of candidate MMP biomarker of cancer between the former stud-
ies and this study. 
Compared to this study and predecessors, numbers of overexpression of MMPs 
according to in cancer with this study have not been successful as tumor biomarkers 
analyzed in the former research, for instance, MMP8, MMP25, MMP20, MMP23 as 
potential biomarkers for metastasis breast cancer; And maybe MMP3, MPP10, 
MPP11, MPP12, MPP13, MPP14 as candidate biomarkers for NSC lung cancer; 
MPP3 for colorectal cancer as potential biomarkers. Those candidates are the novel 
potential tumor biomarkers that should be analyzed with various detection strategies. 
There are some in common can be found by comparing between previous work with 
this work, like MPP1 as tumor biomarker for Colorectal cancer is confirmed both in 
this study and the former studies [Baker EA et al.,2003]. MMP7 for Colorectal cancer 
biomarker, MMP1 for lung cancer.  
Scott A. Tomlins et al. have reported on, those four genes, CACNA1D, KCNS3, 
LAMC2, and PLA1A have a greater correlation with TMPRSS2/ERG fusion across 
multiple prostate cancer profiling studies, also LAMC2, KCNS3, and PLA1A as di-
rect targets of ERG were identified [Scott A et al., 2008].  
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The gene expression matrices in this study were also used to evaluate the expres-
sion difference between cancer and healthy for these four genes: CACNA1D, 
KCNS3, LAMC2, and PLA1A. Only PLA1A and KCNS3 has funded the difference 
expression between cancer and healthy. KCNS3 were overexpressed in prostate 
cancer, so maybe KCNS3 can also be used as a potential biomarker for prostate 
cancer. 
PLA1A and KCNS3 were not related to any particular cancer pathway in KEGG 
pathways, KCNS3 was even not involved in any pathways in KEGG pathway data-
bases. 
In conclusion, two genes, and one protein family were considered as novel bi-
omarkers in this study: PLA1A for prostate cancer, MMP14 for NSC lung cancer, 
KCNS3 may have the potential to be a prostate cancer biomarker, the MMPs family 
for many kinds of cancer and may be also indicators for cancer metastasis. 
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5 Discussion 
Those 3 genes, that mentioned in the last chapter, should be tested in a clinical trial: 
the potential of PLA1A and KCNS3 as prostate cancer biomarkers, MMP14 as NSC 
lung cancer biomarker. To understanding the role of these two genes: PLA1A and 
KCNS3 in the occurrence of prostate cancer, a further study should be taken more 
detailed. As the review of Ras pathway in KEGG, PLA1A is a downstream gene of 
the Ras-Raf-MEK pathway, and according to the research of Scott A. Tomlins et al., 
PLA1A is a target gene of TMPRSS2–ERG gene fusion in prostate cancer[Scott A 
et al., 2008]. Up to now, PLA1A is neither in prostate cancer pathway nor in the 
transcriptional misregulation in prostate cancer pathway, from KEGG databases. 
The pathway  of transcriptional misregulation in cancer was shown in appendix 8. 
For more specific studies of those two genes PLA1A and KCNS3, requires the most 
concrete samples to evaluation: healthy individual, prostate cancer with and without 
TMPRSS2–ERG gene fusion. 
The potential of MMPs as various tumor biomarkers has already proved in many 
former studies. For diagnosis, prognosis and predicting therapeutic efficacy of can-
cers, a large-scale screen of expression profiling of MMPs in various cancer is very 
useful for classification and discrimination. The cancer sample should ideally con-
clude the different stages of different cancer subtypes. 
Even those potential tumor biomarkers were found, there are obviously some limi-
tations in this study. The processing of choosing the candidate genes contents some 
subjectivity. Some of the genes that were chosen, there is no significant expression 
difference. And 5 genes were selected on the colorectal cancer pathway, one gene 
MYC was overexpressed in colorectal cancer expression profiling, only MYC has 
the potential as a biomarker of colorectal cancer. More than 20 genes were selected 
in this study, and in those cancer pathways, it contents generous candidate genes. 
If there are some process on the integration of these genes in pathways, and then 
using the transcription data to analyze, the maybe more potential tumor will be found. 
Furthermore, the mechanisms of cancer and signaling pathway are complex and 
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challenging to identify, and lack of appropriate study designs and analytic methods 
aggravates the challenge.  
The selection genes from KEGG is a process that cannot be quantified. There is an 
idea from another direction: at first, analyze the massive transcription data from dif-
ferent type of cancers, then mapping the datasets into KEGG pathway, using the 
machine learning algorithms to label candidate genes with the type of cancers.  
Set the threshold to find differential expression of the candidate genes is also rela-
tively subjective, there is no conclusive, where the settings are. This study was de-
signed to find a good distinction between cancer patients and healthy individuals. 
So a relatively high threshold has been chosen. If you cut down the threshold of 
logFC to 1, There will be a further oncogene be funded. 
These DNA microarray datasets are from the same platform U133 Plus 2.0, so the 
selection of suitable datasets are limited. And in this work, a few types of cancer 
datasets were used for analyzation, the lack of the date sets lead this work to a few 
findings. For expansion of the data sets, the cross-platform microarray data analysis 
is required. But there are also some difficulties, need to consume a lot of time to do 
the normalization of data sets. Because the DNA microarray is expensive, and it is 
very time-consuming to repeat the experiment, so that is very common for a small 
sample of DNA microarray experiment. So some DNA microarray datasets that used 
in this study are also small samples.  
DNA microarray data is easy to have its background noise, and the experimental is 
poorly repeatability, is now being replaced by RNA-seq technology. For a large 
screen of tumor biomarkers, RNA-seq should be also an option. In the following 
table, the Technical advantages of RNA-seq were discussed. 
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Table  5.1  compares RNA-seq technology and DNA microarray[Gao Shan et al.,2014]   
For the follow-up study of MMPs, using RNA-seq method to carry out large-scale 
screening, is also a good choice. 
 
 
 
 
 
 
 
 
 
 
DNA microarray RNA-seq technology
Bibliographye sequence need No need
Dynamic range Small Big
Background noise Big Small
Affected by degradation Big Small
Sequence variation Big Small
Transcriptional group direction Unable to detect Detectable
Repeatability. Normal High
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6 Perspective 
As for the methodology, selection of candidate genes is limited to those genes, 
which already studied in the KEGG cancer pathways. Even though, some novel 
candidates were found with this method. However, that would result in very few out-
comes, either candidate genes were already studied as biomarkers, or there is no 
further information to support these results. It is questionable how many candidate 
genes from KEGG is available to be considered as “novel”. For the study of PLA1A, 
may provide some new findings of the prostate cancer pathway. A further research 
can be taken like this: using the model that provided in this work, find few candidates, 
then mapping them to the PPI network, using a different strategy to detect more 
candidate biomarkers.  
The identification of the function of MMPs in cancer growth and metastasis can pro-
vide a large number of candidate tumor biomarkers and many effective anti-cancer 
drug targets. For enhancing this method, using the huge amount of data in the GEO 
database can be a big support: choosing different platform data expression data of 
different cancer gene to analysis, to achieve the large screen processing for tumor 
biomarkers and a global perceive of the whole cancer pathway. To achieve that, the 
integration of the existing GEO DNA microarray datasets will be necessary, and 
suitable algorithm of normalization for cross-platform datasets is required. Then 
mapping the expression profiling to the KEGG pathways, using the different algo-
rithms to classify these genes. 
Before those candidate biomarkers: MMP14, PLA1A, MMPs and KCNS3 can be put 
into clinic use, it must undergo several stages of confirmation, validation, and qual-
ification for usage [Wagner,2002]. Analytical validation is the procedure of evaluat-
ing the assay or measurement performance characteristics, while qualification is the 
evidentiary step of connecting a biomarker with the biology and clinical endpoints 
(that is, clinical validity and utility).  
A future study with RNA-seq technology might provide more sensitive expression 
profiling and more comprehensive set of transcripts. Cause some genes in cancer 
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pathway has no probe on the DNA Microarray platform: such as gene CSNK1A1L 
of breast cancer pathway.  
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7 Summary 
Tumor biomarkers have important significance in the diagnosis of cancer and per-
sonalized therapy for cancer. And this study is centered around the cell signaling 
pathway to select a number of genes that may be related to the occurrence of cancer. 
Then some cancer microarray data have downloaded from the GEO database. 
Those datasets were integrated and analyzed. Several expression matrices were 
generated. These candidate genes were tested in the matrices, to evaluate the po-
tential to be a tumor biomarker of those gene candidates. This evaluation model is 
simply considered that gene expression profiling as the measurement for the poten-
tial. 
As result, nine genes were considered as candidate genes, including MYC, BIRC5, 
CCND1, PLA1A, MMP14, PPARG, FOS, HES1, and MAPK7, five of them are over-
expressed in cancer tissue, and they were deeply discussed. 
Because the MYC BIRC5 are oncogenes, is associated with many types of cancer, 
and already being considered as tumor biomarkers. Previous studies have found 
that CCND1 gene has the potential as a biomarker for breast cancer, but the former 
research didn't bring CCND1 to the clinic use. Gene MMP14 is also highly Associ-
ated with cancer, although this gene is selected from non-cancer and non-oncogene 
pathways in KEGG pathway database. Because this gene located on the cell sur-
face, it will be easier to detected in clinic test as a biomarker. Recently, it was tested 
as a tumor biomarker for Head and Neck Squamous Cell Carcinoma [Lusia Sepi-
ashvili et al., 2012]. In this study, it also has the potential to be a biomarker for NSC 
lung cancer. PLA1A is very close associated with    TMPRSS2 /ERG gene fusions, 
and TMPRSS2/ERG gene fusions are also connected with the occurs of prostate 
cancer. The potential of MMP14 and PLA1A as biomarkers would be studied with 
further methods. 
Two of these five genes has the great potential to become the tumor biomarkers, 
and gene MPP14 lead me to one protein family, which have great potential as bi-
omarkers for many kinds of cancer type.  
48  7 Summary 
 
Considering the limited datasets and the not comprehensive analyzation of cancer 
pathways, this method can only be considered as a pre-experiment. 
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